Trial
NCT03729401
Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ottawa Heart Institute Research Corporation
Collaborators
—
Condition
Coronary Artery Disease
Intervention
Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily
Why stopped
Testing supplies unavailable.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-06